Ocultar
Mostrar todos
Envíe este artículo por correo electrónico 
La Ciencia detrás de la vacunas contra SARS CoV-2
Resumen
Palabras clave
Texto completo:
PDFReferencias
Brisse M, Vrba SM, Kirk N, Liang Y y Ly H. 2020. Emerging concepts and technologies in vaccine development. Frontiers in Immunology11:583077.
Dong Y, Dai T, Wei Y, Zhan L, Zheng M y Zhou F. 2020. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduction and Targeted Therapy 5: 237
Folegatti PM, Ewer KJ, Aley PK, et al. 2020. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 396:467–478.
Gao Q., Bao L, Mao H, et al. 2020. Development of an inactivated vaccine candidate for SARS-CoV-2. Science 369:77–81.
Hall V, Foulkes S, Insalata F, et al. 2022. Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection. The New England Journal of Medicine 386: 2534-2535.
Jackson LA, Anderson EJ, Rouphael NG, et al. 2020. An mRNA Vaccine against SARS-CoV-2—preliminary report. New England Journal of Medicine. 383: 20
Ksiazek TG, Erdman D, Goldsmith CS, et al. 2003. A Novel Coronavirus associated with severe acute respiratory syndrome. The New England Journal of Medicine 348: 1953-1966.
Logunov DY, Dolzhikova IV, Zubkova OV, et al. 2020. Safety and immunogenicity of an rAd26 and rAd5 vector based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet.396: 887–897.
Moore KM, Jackwood MW, Hilt DA. 1996. Avian Infectious bronchitis virus:
RNArecombination in vitro. Proceedings of the 45th western Poultry Disease
Conference, Cancun, Mexico.
Muñoz Valle JF, Sánchez-Zuno GA, Matuz-Flores MG, et al. 2022. Efficacy and Safety of Heterologous Booster Vaccination after Ad5-nCoV (CanSino Biologics) Vaccine: A Preliminary Descriptive Study. Vaccines 10: 400.
Pardi N, Hogan MJ, Porter FW y Weissman, D. 2018. mRNA vaccines a new era in vaccinology. Nature Reviews Drug Discovery 17:261–279.
Ponce de León S, Torres M, Soto-Ramírez LE, et al. 2022. Safety and immunogenicity of a live recombinant Newcastle 1 disease virus-based 2 COVID-19 vaccine (Patria) administered via the intramuscular or intranasal 3 route: Interim results of a non-randomized open label phase I trial in Mexico. medRxiv preprint.
Rossi AH, Ojeda DS, Varese A, et al. 2021. Sputnik V vaccine elicits seroconversion and neutralizing capacity to SARS-CoV-2 after a single dose. Cell Reports Medicine 2.
Ulmer JB, Valley U y Rappuoli R. 2006. Vaccine manufacturing: challenges and solutions. Nature Biotechnology 24:1377–1383.
Wolff JA, Malone RW, Williams P, et al. 1990. Direct gene transfer into mouse muscle in vivo. Science 247:1465–1468.
Yu L, Wang Z, Jiang Y, et al. 2001. Molecular epidemiology of Infectious Bronchitis Virus isolates from China and South-East Asia. Avian Diseases 45: 201-209.
Zhang NN, Li XF, Deng YQ, et al. 2020. A Thermostable mRNA Vaccine against COVID-19. Cell 182:1271–1283.
Zhu FC, Li YH, Guan XH, et al. 2020. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 395:1845–1854.
DOI: http://dx.doi.org/10.56369/BAC.4462
Copyright (c) 2022 Edwin José Gutiérrez Ruiz, Roger Ivan Rodríguez Vivas, José Alberto Rosado Aguilar, Eduardo Gutiérrez Blanco, Manuel Emilio Bolio González
Este obra está bajo una licencia de Creative Commons Reconocimiento 4.0 Internacional.
Bioagrociencias, revista electrónica, es una publicación semestral editada por la Universidad Autónoma de Yucatán, a través de la Facultad de Medicina Veterinaria y Zootecnia, km. 15.5 carretera Mérida-Xmatkuil s/n, Mérida, Yucatán, México. Tel. 999 942 32 00. Editor Responsable: Alfonso Aguilar-Perera (alfonso.aguilar@correo.uady.mx), 04-2017-062617313100-203, ISSN 2007-431X.